

Special Issue

Antibiotic Resistance and Intensive Care Unit

Message from the Guest Editors

More than one-third of intensive care unit (ICU) patients develop an infection during their stay and antibiotic resistance is a serious challenge in the treatment of such conditions. Of particular concern is the misuse or overuse of antibiotics, which has led to the development of resistant or super-resistant bacterial strains.

Minimization of broad-spectrum antibiotic use and prompt antibiotic administration aid in the reduction of antibiotic resistance. However, areas where further research is required are investigation into the heterogeneity of critically ill patients and the need for new antibacterial drug development. The purpose of this Special Issue of *Antibiotics* is to present a collection of the latest high quality research in this field, with a particular focus on antibiotic therapy against multidrug resistant bacteria in intensive care patients.

Guest Editors

Dr. Ceccarelli Giancarlo

University Hospital Policlinico Umberto I, University of Rome Sapienza, Rome, Italy

Dr. Francesco Alessandri

Assistant Professor, Department of Anesthesia, Critical Care and Pain Medicine, Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions

closed (12 August 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/52222

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)